Clinical Ink Acquires Digital Artefacts
Clinical Ink, a global clinical trial data and technology company, has announced its acquisition of Digital Artefacts, a digital endpoint-based technology company with a modular platform for complex cognitive, behavioral, and physiological data capture.
The combination of Clinical Ink and Digital Artefacts will provide benefits including:
- Scientifically validated neurocognitive assessment and research tools (50+ modular, self-administered assessments)
- Combination of standardized eCOA scales/assessments with digital endpoints to produce quantitative patient outcomes
- Trial specific remote active and passive behavioral assessment, including wearable and sensor data
- Precision Real-World Data and insights across complex therapeutic areas for which cognition is an endpoint
- Scaled delivery capabilities in logistics, helpdesk, project management, and device acquisition/support for DCTs
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
